Ligand Pharmaceuticals Incorporated (LGNZZ)

OTCMKTS · Delayed Price · Currency is USD
0.1200
0.00 (0.00%)
At close: Jul 16, 2025
-25.00%
Market Cap2.40B
Revenue (ttm)181.49M
Net Income (ttm)-132.62M
Shares Outn/a
EPS (ttm)-7.11
PE Ration/a
Forward PE20.18
Dividendn/a
Ex-Dividend Daten/a
Volume11,720
Average Volume3,935
Open0.1300
Previous Close0.1200
Day's Range0.1200 - 0.1300
52-Week Range0.1169 - 0.1960
Beta0.71
RSI43.33
Earnings DateAug 6, 2025

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neurobla... [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 1987
Employees 68
Stock Exchange OTCMKTS
Ticker Symbol LGNZZ
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.